ELSEVIER

SEMINARS IN PERINATOLOGY

AUTHOR INDEX

Abman, S.H., 123
Abuhamad, A., 377
Anderson, I.J., 144
Arkel, Y.S., 150

Bahado-Singh, R.O., 209
Bahrami, K.R., 15
Bartlett, R.H., 2
Benacerraf, B.R., 387
Benn, P., 252
Berkowitz, R.L., 281, 312, 396
Bradley, L.A., 135
Britt, D.W., 321, 364
Bulas, D., 58

Canick, J.A., 203
Cass, D.L., 104
Cleary-Goldman, J., 240, 281, 312, 381, 396, 406
Conrad, S.A., 24
Crombleholme, T.M., 296
Cuckle, H., 252

Dalton, H.J., 24
D'Alton, M.E., 240, 312, 367, 381, 406
Delgado, J., 94
Deprest, J., 94
Devine, P.C., 69

Edusa, V., 338
Elliott, J.P., 305
Evans, M.I., 215, 321, 364

Farrow, K.N., 8
FETO Task Group, 94
Fliman, P., 8

Gaddipati, S., 282
Galen, R.S., 364
Gargamta, C.L., 164
Glass, P., 58
Graham, G., 69
Graham, G.M. III, 282
Gratacos, E., 94
Greenough, A., 94

Hackshaw, A.K., 225
Haddow, J.E., 247
Harkness, U.F., 296
Hines, M.H., 34

Ivy, D.D., 123

Jani, J., 94
Jonas, R.A., 51

Khan, A.M., 118
Khoury, M.J., 135
Kinsella, J.P., 123
Kloza, E.M., 247
Knight, G.J., 247
Ku, D.-H.W., 150

Lally, K.P., 67, 112, 118
Lange, P., 40
Langhoff-Roos, J., 150
Luke, B., 349

Macones, G.A., 263
MacRae, A.R., 203
Mahoney, M.J., 209
Matteson, K.J., 144
Mendilcioglu, I., 209
Mennuti, M.T., 189
Moore, C.A., 135
Moya, F.R., 67, 112

Nakhuda, G.S., 355
Naulaers, G., 94
Nicolaides, K.H., 94, 190
Norwitz, E.R., 338

Odibo, A., 263
Oz, U.A., 209

Paidas, J.M., 150
Palomaki, G.E., 247
Park, J.S., 338
Platt, L.D., 258
Powell, D., 40

Reddy, U.M., 189
Rehm, H.L., 173
Rodeck, C., 225
Rosen, T., 367
Rothenbach, P., 40
Rottier, R., 86
Rudnicka, A., 225
Ryeus, P.T., 24

Sauer, M.V., 355
Seashore, C.J., 182
Seashore, M.R., 182
Short, B.L., 1, 45
Simpson, L.L., 330
Slavotinek, A.M., 77
Smith, W.E., 164
Spadola, A.C., 330
Steinhorn, R.H., 8

Tibboel, D., 86

Vandecruys, H., 94
Van Meurs, K.P., 15

Wald, N.J., 225
Wapner, R.J., 215, 236, 402
Wenstrom, K.D., 195, 219
West, S.D., 129
Williams, J., 247
Wilson, J. M., 129
Wright, D., 252

SUBJECT INDEX

ABR (auditory brainstem responses), 173-174
Abruptio placentae, thrombophilia and, 155-156, 157
Acardiac twins, 330
ACCE process, 138-139, 140-141
Acetylcarnitine analysis, for inborn errors of metabolism, 170-171
ACMB/HRSA Report newborn screening core panel, 183, 184
Acute tubular necrosis, from ECMO, 20
Adult respiratory distress syndrome (ARDS), ELSO for, 2-3, 25, 28, 31
AFP. *See* Alpha-fetoprotein
Air emboli, from ECLS, 52
Alkalosis, to produce pulmonary vasodilation, 11
Alpha-fetoprotein (AFP). *See also* Quadruple serum screen; Triple screen
  detection rate for given false-positive rate, 253-256
  integrated screening results and, 220-221
Alpha-fetoprotein (AFP). *See also* Quadruple serum screen; Triple screen (*Continued*)
  in multiple gestation, 316, 398
  neural tube defects and, 203
  second trimester aneuploidy risk and, 314-315
Alpha stat strategy, 54-55
Amino acid disorders, diagnostic tests for, 170, 184, 185-186
Aminocaproic acid, for CDH repair on ECMO, 120-121
Ammonia, inborn errors of metabolism and, 167
Amniocentesis, 392
  diagnosis of monoamniotic twins, 290-291
  Down syndrome detection, 367, 387, 392
  historical perspective, 215-216
  mid-trimester, safety of, 217-218

ELSEVIER

SEMINARS IN PERINATOLOGY

AUTHOR INDEX

Abman, S.H., 123
Abuhamad, A., 377
Anderson, I.J., 144
Arkel, Y.S., 150

Bahado-Singh, R.O., 209
Bahrami, K.R., 15
Bartlett, R.H., 2
Benacerraf, B.R., 387
Benn, P., 252
Berkowitz, R.L., 281, 312, 396
Bradley, L.A., 135
Britt, D.W., 321, 364
Bulas, D., 58

Canick, J.A., 203
Cass, D.L., 104
Cleary-Goldman, J., 240, 281, 312, 381, 396, 406
Conrad, S.A., 24
Crombleholme, T.M., 296
Cuckle, H., 252

Dalton, H.J., 24
D'Alton, M.E., 240, 312, 367, 381, 406
Delgado, J., 94
Deprest, J., 94
Devine, P.C., 69

Edusa, V., 338
Elliott, J.P., 305
Evans, M.I., 215, 321, 364

Farrow, K.N., 8
FETO Task Group, 94
Fliman, P., 8

Gaddipati, S., 282
Galen, R.S., 364
Gargamta, C.L., 164
Glass, P., 58
Graham, G., 69
Graham, G.M. III, 282
Gratacos, E., 94
Greenough, A., 94

Hackshaw, A.K., 225
Haddow, J.E., 247
Harkness, U.F., 296
Hines, M.H., 34

Ivy, D.D., 123

Jani, J., 94
Jonas, R.A., 51

Khan, A.M., 118
Khoury, M.J., 135
Kinsella, J.P., 123
Kloza, E.M., 247
Knight, G.J., 247
Ku, D.-H.W., 150

Lally, K.P., 67, 112, 118
Lange, P., 40
Langhoff-Roos, J., 150
Luke, B., 349

Macones, G.A., 263
MacRae, A.R., 203
Mahoney, M.J., 209
Matteson, K.J., 144
Mendilcioglu, I., 209
Mennuti, M.T., 189
Moore, C.A., 135
Moya, F.R., 67, 112

Nakhuda, G.S., 355
Naulaers, G., 94
Nicolaides, K.H., 94, 190
Norwitz, E.R., 338

Odibo, A., 263
Oz, U.A., 209

Paidas, J.M., 150
Palomaki, G.E., 247
Park, J.S., 338
Platt, L.D., 258
Powell, D., 40

Reddy, U.M., 189
Rehm, H.L., 173
Rodeck, C., 225
Rosen, T., 367
Rothenbach, P., 40
Rottier, R., 86
Rudnicka, A., 225
Ryeus, P.T., 24

Sauer, M.V., 355
Seashore, C.J., 182
Seashore, M.R., 182
Short, B.L., 1, 45
Simpson, L.L., 330
Slavotinek, A.M., 77
Smith, W.E., 164
Spadola, A.C., 330
Steinhorn, R.H., 8

Tibboel, D., 86

Vandecruys, H., 94
Van Meurs, K.P., 15

Wald, N.J., 225
Wapner, R.J., 215, 236, 402
Wenstrom, K.D., 195, 219
West, S.D., 129
Williams, J., 247
Wilson, J. M., 129
Wright, D., 252

SUBJECT INDEX

ABR (auditory brainstem responses), 173-174
Abruptio placentae, thrombophilia and, 155-156, 157
Acardiac twins, 330
ACCE process, 138-139, 140-141
Acetylcarnitine analysis, for inborn errors of metabolism, 170-171
ACMB/HRSA Report newborn screening core panel, 183, 184
Acute tubular necrosis, from ECMO, 20
Adult respiratory distress syndrome (ARDS), ELSO for, 2-3, 25, 28, 31
AFP. *See* Alpha-fetoprotein
Air emboli, from ECLS, 52
Alkalosis, to produce pulmonary vasodilation, 11
Alpha-fetoprotein (AFP). *See also* Quadruple serum screen; Triple screen
  detection rate for given false-positive rate, 253-256
  integrated screening results and, 220-221
Alpha-fetoprotein (AFP). *See also* Quadruple serum screen; Triple screen (*Continued*)
  in multiple gestation, 316, 398
  neural tube defects and, 203
  second trimester aneuploidy risk and, 314-315
Alpha stat strategy, 54-55
Amino acid disorders, diagnostic tests for, 170, 184, 185-186
Aminocaproic acid, for CDH repair on ECMO, 120-121
Ammonia, inborn errors of metabolism and, 167
Amniocentesis, 392
  diagnosis of monoamniotic twins, 290-291
  Down syndrome detection, 367, 387, 392
  historical perspective, 215-216
  mid-trimester, safety of, 217-218

Amniocentesis, 392 (*Continued*)
in multiple gestation, 317
thickened nuchal fold, 195
Amnioreduction, for twin-to-twin transfusion syndrome, 299-300, 302
Amniorrhexis, after FETO, 102
Amniotic membrane, NT measurement and, 379-380
Analytic validity, of DNA-based testing, 138
Anemia, iron-deficiency, 351
Aneuploidy. *See also* Trisomies; Turners syndrome
cystic hygroma and, 370
nuchal translucency and, 195-196
risk, in multiple gestation, 397
second trimester screening for, 314-315
tricuspid regurgitation and, 371
zygosity and, 312-313
Animal models, of congenital diaphragmatic hernia, 81-83
Anion gap, 165
Antibiotic prophylaxis
for delayed interval delivery in multiple gestation, 289-290
for preterm birth prevention, 345
Anticoagulation, for ECMO, 16-19
Antithrombin deficiency, 152
A priori risk assessment, for second trimester testing, 191, 221-222
ARDS (adult respiratory distress syndrome), ELSO for, 2-3, 25, 28, 31
Aromatase inhibitors, for ovulation induction, 356
ART. *See* Assisted reproductive technology
Arterial inflow during ECLS, causing brain ischemia, 53
Arterial steal, 53
Asphyxia, in ECMO infants, 45
Assisted reproductive technology (ART)
advanced maternal age and, 358
controlled ovarian hyperstimulation with gonadotropins, 356-358
higher order multiple pregnancies and, 312, 355-356
implantation rate and, 358-359
maternal age and, 322-323
multiple gestation and, 396
number of embryos transferred and, 359-360
ovulation induction, 356
practices, legislation on, 360
pregnancies achieved by, 321
in vitro fertilization, 358
Athletic ability prediction, genetic testing for, 136, 137
Auditory brainstem responses (ABR), 173-174

Beckwith-Wiedemann syndrome, 79
Bedrest, to prevent preterm birth, 345
BESST (birth emphasizing the successful singleton at term), 360
Beta-human chorionic gonadotropin (beta-hCG), 260, 314-315
Bipolar coagulation, for selective termination, 333, 334, 335
Birth emphasizing the successful singleton at term (BESST), 360
Birth weight, ECMO for neonatal respiratory failure and, 16
Black-lung persistent pulmonary hypertension of the newborn, 9-10
Blastocyst culture, implantation rates and, 358-359
Bleeding
intracranial hemorrhage. *See* Intracranial hemorrhage
postcardiotomy, 38
posterior-fossa hemorrhage, in ECMO patients, 47
pulmonary hemorrhage, in ECMO patients, 16-17
vaginal, first trimester, 243-244
Blood gas analysis, for inborn errors of metabolism, 164-165
Blood pressure, maternal
elevation of. *See* Hypertensive disorders of pregnancy
in multiple gestation, 339
Blood volume, in multiple gestation, 338-339, 340
Bochdalek hernia (posterolateral CDH), 69, 77
Body mass index
maternal weight gain and, 352-353
obesity, obstetric complications and, 244
Bosentan, 126

Brain injury
from cardiopulmonary bypass, 51
from ECLS, reduction of, 52-56
during ECMO, perfusate oxygen management and, 56
ECMO and, 46-49
hyperventilation and, 46
ischemic during ECLS, causes of, 53-56
perinatal, neurodevelopmental impact of, 61-63
reduction/reversal with ECLS, 51
in TTTS survivors, 302
Bronchial collaterals, 53
BUN Study
independent sequential screening in, 276
methods, 236-237
NT measurements, congenital heart disease and, 409, 410
NT ultrasound quality review method, 383-385
pregnancy termination in, 275
results, discussion of, 237-238
sequential screening and, 373-374

Calcium supplementation, 351
Cannula obstruction, causing brain ischemia, 53
Cannulation, ESMO
cath laboratory procedures, 38
delay, new treatment modalities and, 12-13
femoral arterial, ischemic leg with, 37-38
of neonate, 18
transthoracic, 38
"Capping the membrane lung," 19
Carbohydrate metabolism, multiple gestation and, 349-350
Cardiac catheterization, 38, 127
Cardiac output, maternal, in multiple gestation, 339
Cardiac patients. *See also* Congenital heart disease
ELSO Registry data, 25, 28-30
mechanical and patient-related complications in, 32
Cardiogenic shock, ECMO for, 34-35
Cardiopulmonary bypass (CPB)
brain injury from, 51
failure to wean from, 35
perfusate oxygen management, 56
perfusion hematocrit, 53-54
pH stat strategy, 54-55
reduction of emboli injury, 52
Cardiopulmonary resuscitation (CPR), ECMO during, 30, 35
Cardiovascular system, physiologic adaptations in multiple gestation, 338-339
Carotid artery ligation, 46-47, 58
Catheters, vascular access, development of, 4
CC (clomiphene citrate), 356
CDH. *See* Congenital diaphragmatic hernia
Central nervous system defects, with congenital diaphragmatic hernia, 69, 70
Central venous pressure, monitoring, during ECLS, 52
Centrifugal pump head, 53
Cerebral autoregulation, 46, 48
Cerebral blood flow (CBF), 45-47, 58
Cerebral injury, in ECMO
pre-ECMO events and, 45-46
risk factors for, 46-49
Cerebral monitoring, during ECLS, 52
Cerebral oxygen metabolism ($CMRO_2$), 45, 47
Cerebral palsy, in TTTS survivors, 302
Cerebrovascular imaging, of ECMO-treated infants, 59-60
Cervical cerclage, 290, 345
CFNS (craniofrontonasal syndrome), 79
CGH (comparative genomic hybridization), 146
CHD. *See* Congenital heart disease
Chemistry lab tests, for inborn errors of metabolism, 168, 169
Children, ELSI of genetic testing, 139-140

Cholestatic jaundice, 171
Chorionic villus sampling (CVS)
  access to, 275
  biochemical testing, 403
  confined placental mosaicism and, 403
  contingent on first trimester screen, 374
  for Down syndrome diagnosis, 219, 367
  fetal abnormality risk after, 404-405
  for high-risk pregnancies, 276
  historical perspective, 215-216, 402
  maternal cell contamination, 403
  multifetal pregnancy reduction after, 323, 324
  in multiple gestation, 317-318
  pregnancy loss after, 217, 404
  results, reliability of, 402
  risks from, 217
Chromosomal abnormalities. *See also specific chromosomal disorders*
  A priori risk for, 191
  with congenital diaphragmatic hernia, 69, 80-81
  cystic hygroma and, 409
  diagnosis in multiple gestation, 282
  diagnosis of, 145
  in FASTER trial, 242
  first trimester screening. *See* First trimester screening
  management in multiple gestation, 282-283
  in monozygotic twins, 313
  prognosis for CDH and, 72
  risk, in multiple gestation, 312, 396
Chromosome analysis, 145
Chronic lung disease
  in ECMO-treated infants, 20, 130
  with prolonged mechanical ventilation, 16
Cincinnati modification of Quintero staging system, for twin-to-twin transfusion syndrome, 297-298
Classical compression theory, of lung development interference, 91
Clinical utility, of DNA-based testing, 139
Clinical validity, of DNA-based testing, 138-139
Clinodactyly of fifth digit, in Down syndrome, 390
Clomiphene citrate (CC), 356
Coagulation factors
  deficiency states, 151-153
  pregnancy-induced changes in, 150-151
Coagulopathy, ECMO for neonatal respiratory failure and, 16-17
COH. *See* Controlled ovarian hyperstimulation
Combined screening test
  definition of, 226
  detection rate, 240, 247, 371
  efficacy, *vs.* other screening approaches, 227-228
  false positive rates, 229-230, 231, 240, 247
  in multiple gestation, 315-316, 399-400
  performance, risk cut-off and, 232-233
  vs. integrated screening test, 372-373
Comparative genomic hybridization (CGH), 146
Complement activation, meconium-induced, 9
Complete blood count, inborn errors of metabolism and, 168
Computed tomography, cerebrovascular imaging of ECMO-treated infants, 60
Congenital abnormalities. *See also specific congenital abnormalities*
  first trimester ultrasound of, 408
  with inborn errors of metabolism, 171
  major, on genetic sonogram, 389-390
  in multiple gestation, management of, 400
  structural. *See* Structural anomalies
Congenital diaphragmatic hernia (CDH)
  animal models, 81-83
  anterior or Morgagni hernia, 69
  bilateral, 95
  cardiopulmonary interactions in, 124
  chromosomal defects and, 69, 80-81, 95
Congenital diaphragmatic hernia (CDH) (*Continued*)
  classification of, 69
  clinical presentation, 40-41, 123
  diagnosis, 40-41, 69-71, 104-106
  differential diagnosis, 70, 71
  ethical issues of fetal surgery, 108-109
  etiology, 69, 77
  evidence-based management, 112-115
  "hidden mortality" of, 69, 70, 112
  incidence, 40, 69, 77, 95
  inheritance patterns, 77
  international registry for, 112
  late complications, 124-127
  left-sided, 95, 99
  lung development in, 95
  lung hypoplasia and, 5, 10
  medical management, 41
  mortality rates, 42, 69-70, 112
  NO-cGMP pathway in, 124
  nonsyndromic or isolated, 77-78
  outcome of, 69-70, 95
  patch repair, in ECMO-treated infants, 131
  pathophysiology/pathogenesis, 40, 86, 91
  polymorphisms in, 83
  posterolateral or Bochdalek hernia, 69, 77
  prognosis, 72-74, 95, 105-106
  pulmonary hypertension, late, 124-126
  pulmonary morbidity, 129-130
  right-sided, 95
  severity, stratification of, 105-106
  structural anomalies with, 69, 70, 95
  surfactant deficiency in, 89
  survival rates, 70, 71, 129
  syndromic, 78-80
  teratogens and, 81
  treatment interventions, 95-96. *See also* Extracorporeal membrane oxygenation, for CDH
    controlled treatment studies, lack of, 115
    failure, criteria for, 118-119
    fetal surgery for, 106-109
    pulmonary vasodilator therapy, 123-127. *See also* Inhaled nitric oxide therapy
    surgical repair, 42
    in utero, 40
  in utero lung compression and, 123
  vasculature in, 88-89
Congenital hearing loss. *See* Hearing loss, congenital
Congenital heart disease (CHD)
  blood pH, cerebral blood flow and, 54-55
  with congenital diaphragmatic hernia, 69, 70
  ECMO techniques for, 17, 29, 31, 35-36, 51
  ELSO Registry data, 29, 31, 38-39
  enlarged nuchal translucency and, 199-201
  first trimester screening, 410-411
  increased fetal NT with normal karyotype, 193-194
  indications for ECMO, 34-36
  postoperative support, 35
Conjoined twins, 260-262, 292-293
Contingent sequential screening
  alternative approach, 374
  definition of, 253
  detection rates, 222-223, 253-256
  risk cut-offs, 237-238
  SURUSS trial and, 374
Controlled ovarian hyperstimulation (COH)
  with gonadotropins, 356-358
  reducing risks for multiple pregnancies, 357
  vs. ovulation induction, 356
Cord coagulation, for twin-to-twin transfusion syndrome, 301

Cord ligation, for selective termination, 331-333
Cord occlusion methods, for selective termination, 331
Cornelia de Lange syndrome, 80
Corticosteroids, for congenital diaphragmatic hernia, 113-114
COX-1, 8, 9
CPR (cardiopulmonary resuscitation), ECMO during, 30, 35
Craniofrontonasal syndrome (CFNS), 79
Crown-rump length (CRL)
  NT measurements and, 368-369
  nuchal translucency and, 190, 191, 196
  in pregnancy dating, 407
CVS. *See* Chorionic villus sampling
Cyclooxygenase, 8
Cystic fibrosis
  molecular genetic testing for, 147-148
  newborn screening, 186
Cystic hygroma
  aneuploidy and, 370
  chromosomal abnormalities and, 409
  development of, 199-200
  first trimester determination, 241-242, 408-410
  on genetic sonogram, 389-390
  increased NT and, 191, 368
  septated, 241-242
  in twin pregnancy, 260, 261
Cytogenetic testing, 144
Cytomegalovirus infections, hearing loss from, 176

Deafness. *See* Hearing loss, congenital
Delayed interval delivery, in multiple gestation, 287-290
Delayed neuronal death, 55
Deletions, FISH analysis of, 145
Delta NT method, 196, 197, 275
Denys-Drash syndrome, 78, 79
DET (double embryo transfer), 359
DIA (dimeric inhibin A). *See* Inhibin A
Diagnostic tests, *vs.* screening tests, 364, 365
Diaphragm. *See also* Congenital diaphragmatic hernia
  development of, 88, 91
Dichorionicity, ultrasound determination, 407-408
Dimeric inhibin A (DIA). *See* Inhibin A
DNA-based testing
  decision-making, ACCE process for, 138-139, 140-141
  for newborn screening, 186
Donnai-Barrow syndrome, 80
Doppler ultrasound assessment, of ductus venosus, 370-371
Double embryo transfer (DET), 359
Double lumen cannulas, for pediatric patients, 27
Double screening test, 226, 227-228
Down syndrome, CDH and, 81, 82
Down syndrome screening
  access issues, 269-270
  analytes, 219, 220. *See also specific analytes*
  center-specific NT medians, 197
  combined screening method for, 237, 275-276
  diagnostic characteristics/cost of, 268
  economic analyses, 263-266
  fetal death rate, 191
  first trimester. *See* First trimester screening
  historical aspects, 267, 367
  iliac angle and, 390
  informed consent for, 278-279
  integrated first and second trimester tests. *See* Integrated screening test
  invasive testing, informed consent for, 193
  meta-analysis of mid-trimester sonographic markers, 211-212
  mid-trimester genetic sonogram for. *See* Genetic sonogram
  nuchal translucency-based. *See* Nuchal translucency ultrasound
  performance prediction, using multivariate Gaussian modeling, 252-257
  public health implications, 267-271
Down syndrome screening (*Continued*)
  pyelectasis and, 389
  second trimester. *See* Second trimester screening
  sonographic markers, first-trimester, 192
Drugs
  CDH-associated, 69
  NSAIDs, idiopathic PPHN and, 9
  tocolytic, 309, 345
DSL inhibin A assay, reliability of, 205
Duchenne muscular dystrophy, molecular genetic testing for, 148
Ductus venosus, Doppler ultrasound assessment, 370-371
Duplications, FISH analysis of, 145

Echocardiography
  of twin-to-twin transfusion syndrome, 299
  for VA ECMO monitoring, 37
ECLS. *See* Extracorporeal life support
ECMO. *See* Extracorporeal membrane oxygenation
Economic analyses
  critical components, 263
  of Down syndrome screening, 263-265
  limitations of, 265-266
ECPR (ECMO during CPR), 30
EFNB1 gene, craniofrontonasal syndrome and, 78, 79
Ehlers-Danlos syndrome, 80
Electroencephalography, post-VA ECMO, 47
Electrolyte analysis, for inborn errors of metabolism, 164-165
ELISA inhibin A assay, reliability of, 205
ELSI (ethical, legal and social implications), of genetic testing, 139-140
ELSO Registry
  adult data, 25, 28
  cardiac population data, 25, 28-30
  cardiac support data, 38-39
  Case Report Form, 32
  CDH survivor data, 119
  complications, data on, 30, 31, 32
  ECMO usage, 20-21
  in future, 32
  gestational age, survival and, 16
  history of, 30-32
  neonatal data, 25-27
  overview of, 25
  pediatric data, 25, 27-28
  survival rates for ECMO-treated infants, 121
  use of NO, HFV and surfactant before ECMO, 12
Endothelial nitric oxide synthase (eNOS), 8, 9-10, 124
Esophageal dilation, in utero, 130-131
Essential fatty acid requirements, 352
Estradiol in COH, multiple pregnancy risks and, 357
Estriol, unconjugated. *See also* Quadruple serum screen
  detection rate for given false-positive rate, 253-256
  integrated screening results and, 220-221
  second trimester aneuploidy risk and, 314-315
  in triple screen. *See* Triple screen
ET-1, idiopathic PPHN and, 10
Ethical, legal and social implications (ELSI), of genetic testing, 139-140
Ethics
  deaf community issues, 179-180
  of fetal surgery for CDH, 108-109
  of informed consent, 277-278
  informed consent for first trimester screening, 278-279
Evidence-based management, of congenital diaphragmatic hernia, 112-115
EXIT procedure (ex utero intrapartum treatment), 96, 97, 107
Extracorporeal life support (ECLS)
  air emboli reduction methods for, 52
  cannulation delay, new treatment modalities and, 12-13
  cardiopulmonary bypass for. *See* Cardiopulmonary bypass
  clinical trials, 5
  ECMO. *See* Extracorporeal membrane oxygenation

Extracorporeal life support (ECLS) (*Continued*)
embolic injury, reduction of, 52
future of, 5-6
historical aspects, 1, 2
for neonatal respiratory failure, 4
number of cases annually, 25
technical methods for reducing particulate emboli, 52
venous drainage during, 53
Extracorporeal Life Support Organization (ELSO), 3, 24-25. *See also* ELSO Registry
Extracorporeal membrane oxygenation (ECMO)
for cardiac support, 38-39
for CDH, 41-43, 51, 113
efficacy of, 119-120
historical aspects, 118
indications, 41
iNO therapy for pulmonary hypertension after, 126
long-term outcome for, 121
number of cases annually, 26
with perfluorocarbon instillation, 113, 115
surfactant metabolism and, 89
during surgical repair, 120-121
survivors. *See* Extracorporeal membrane oxygenation-treated infants
timing of, 119
types of, 120
usage/exclusion criteria for, 118-119, 120
center/facility, transport to, 12
cerebral injury, 45-49
circuit, heparin-bonded or carmeda-coated, 38
clinical trials, 3
complications, 19-20
deaths, intracranial hemorrhage and, 47
definition of, 15
demographic changes, 20-21
diseases treated with, 17
in ELSO registry, 26
equipment, 4-5, 37
exclusion criteria, 42
femoral cannulation, ischemic leg with, 37-38
historical aspects, 1, 2-3, 24
in hypoxemic respiratory failure, 118
indications for, 34-36, 41
interaction with new therapies, 12-13
for late pulmonary hypertension in congenital diaphragmatic hernia, 124
maintenance, for cardiac support, 37
multidisciplinary team, 17
need for, iNO and, 11, 12
for neonatal respiratory failure. *See* Neonatal respiratory failure, ECMO for
open chest, considerations for, 38
oxygenators, 4, 37, 38
patient management, 18-19
pCO_2, 55
perfusate, 54-56
perfusion hematocrit, 53-54
pH management during, 54-55
procedure, 17-18
pumps, 37
respiratory entry criteria, 16, 17
risk factors, 46-49, 58-59
risks from, 45
survival rates, 25-26
team for, 17
techniques, 36, 42. *See also* Venoarterial ECMO; Venovenous ECMO
weaning, 37
Extracorporeal membrane oxygenation-treated infants
developmental delay in, 131-132
gastroesophageal reflux in, 130-131
hearing loss in, 132
Extracorporeal membrane oxygenation-treated infants (*Continued*)
neurocognitive deficits in, 131-132
nutritional morbidity and growth in, 130
orthopaedic deformities in, 132
patch repair for, 129, 131
pulmonary morbidity in, 129-130
pulmonary recovery in, 125-126
recurrence in, 132
recurrent hernia in, 132
Ex utero intrapartum treatment (EXIT), 96, 97, 107

Factor V Leiden, 136, 137, 150, 153, 155
FASTER Research Consortium, 273
FASTER Trial, 195, 197, 273, 367
chromosomal abnormalities in, 242
combined test and, 374, 392-393
contingency screening and, 374
cystic hygroma and, 370
data collection/statistical analysis, 241
detection rate with NT ultrasound, 381
enlarged NT, cardiac anomalies and, 200
first trimester combined screen vs. integrated screening, 372-373
integrated screening program in, 276
maternal age and, 244-245
maternal body mass index and, 244
nasal bone analysis, 199, 242-243, 245, 370
NICHD Multicenter Down Syndrome Screening Study and, 240-241
NT measurement, congenital heart disease and, 410-411
NT screening performance, 268-269, 369, 372
NT ultrasound quality review method, 385
PAPP-A and, 244, 245
septated cystic hygroma and, 241-242, 245, 409-410
study population, 240-241
success rates for NT measurements, 368-369
SURUSS Trial and, 231
triple vs. quad markers, 204-205
vaginal bleeding and, 243-244
Fatty acid oxidation disorders, identified by MS/MS, 185-186
FBN-1 gene, 89
FDA regulation, of biomedical devices, 4-5
Femoral arterial cannulation, ischemic leg with, 37-38
Femur length determination, in genetic sonogram, 388
Fetal bowel echogenicity, 389
Fetal echocardiography, of CDH prognosis, 73
Fetal fibronectin (fFN), 308, 344-345
Fetal growth discordance, multiple gestation and, 343
Fetal head position, neutral, 379
Fetal loss. *See* Pregnancy loss
Fetal Medicine Foundation (FMF), 191
Fetal Medicine Foundation Study (FMF Study), 368, 370, 372
Fetal nuchal translucency. *See* Nuchal translucency ultrasound
Fetal reduction. *See* Multifetal pregnancy reduction
Fetal surgery
for congenital diaphragmatic hernia, 106-109
experimental background, 106
with FETO, 99-100
Fetal syndromes, associated with congenital diaphragmatic hernia, 70
Fetal tracheal occlusion
approaches for, 107-108. *See also* Fetoscopic endoluminal tracheal occlusion
to reduce CDH severity, 90, 95-96
technique, 40
Fetendo Clip, 108
Fetoscopic endoluminal tracheal occlusion (FETO)
clinical program for, 96
complications of, 102
consent, 96
controls, contemporary, 101-102
data collection and controls, 97
early experience, 97, 99

Fetoscopic endoluminal tracheal occlusion (FETO) (*Continued*)
with fetal surgery, 99-100
neonatal outcome, 101
operative technique, 96-98
postnatal management, 97
postoperative course, 100
reversal, 97, 100-101
selection criteria for, 96, 99, 100, 102
Fetoscopic laser photocoagulation, for twin-to-twin transfusion syndrome, 300-301, 302-303
Fetus, mid-sagittal plane, for NT measurement, 378-379
fFN (fetal fibronectin), 308, 344-345
Fibroblast growth factors, in lung development, 87
First trimester, down syndrome screening, 195-201, 272
First trimester screening, 367. *See also specific analytes*
advantages of, 219-220, 247
analytes, 219, 253
availability of, 275
BUN study, 236-238
chorionicity determination, 407-408
for chromosomal defect risk, 191-192
combined, *vs.* integrated screening, 372-373
congenital heart disease and, 410-411
detection rate, 237, 253-256
DNA microarray technology for, 138
for Down syndrome, 272
ductus venosus assessment, 370-371
economic implications, 263-266
gestational age and, 228-229
in higher-order multiple gestation, 306
informed consent for, 278-279
intact *vs.* free hCG, 198
integrated with second trimester tests, 220-221
invasive testing, informed consent for, 193
maternal attitudes and, 192-193
maternal serum marker abnormalities, adverse outcomes and, 411
nasal bone analysis, 198-199, 370
with NT and maternal age, 191-192
with NT ultrasound, 381
of nuchal translucency. *See* Nuchal translucency ultrasound
for pregnancy dating, 406-407
as risk assessment for chromosomal abnormalities, 191-192
sequenced with second trimester tests, 221
serum levels, 371-373
sonographic markers, 192
structural anomaly determination from, 408
tricuspid regurgitation, 371
in twin pregnancies, 192, 258-262
two-stage, individual risk-oriented, 192-193
ultrasound markers, 368-371
First trimester screening tests, over-estimation biases, 231
Fluorescence *in situ* hybridization (FISH), 143-146, 323
FMF study, 368, 370, 372
Fog2 gene, CDH and, 82
Free βhCG
in combined screening test. *See* Combined screening test
detection rate for given false-positive rate, 253-256
discriminatory rate, 371
discriminatory value *vs.* total hCG, 371-372
for Down syndrome screening, 219, 272
integrated screening results and, 220-221
in multiple gestation, 259, 398
with PAPP-A, NT and maternal age, 197
vs. intact hCG, 197-198
Frontothalamic distance, in Down syndrome, 390
Fryns syndrome, congenital diaphragmatic hernia and, 78, 80

Gastroesophageal reflux, in CDH survivors, 130-131
Gata4 gene, CDH and, 82
Gene-disease associations, 138
Genes, in lung development, 87, 88
GeneTests, 136, 140
Genetic counseling
for congenital hearing loss, 179-180
on invasive genetic testing for multiples, 316
for multiple gestation, 313, 397-398
Genetic disorders. *See also specific genetic disorders*
with hearing loss, 174-176, 177
laboratory diagnosis of, 145-146
Genetic laboratories, specialty, 144
Genetic sonogram
abnormal, determination of, 209-210
choice of markers for, 209
combined markers for, 391-393
diagnostic sensitivity of, 210
Down syndrome detection improvement and, 387
extended, 212-213
false-positive rates, 210
femur length determination, 388
humerus length determination, 388-389
hyperechoic bowel and, 389
iliac angle in, 390
in low-risk patients, 210-211
major congenital anomalies on, 389-390
markers, newer, 390-391
meta-analysis of mid-trimester markers, 211-212
nuchal fold measurement, 387-388
pyelectasis and, 389
Genetic testing
for congenital hearing loss, 173
decision-making, ACCE process for, 138-139, 140-141
in diagnosing hearing loss etiology, 176-179
ELSI of, 139-140
family scenarios, 140-141
family scenarios for, 135-136, 137
ordering of, 136, 138
for thrombophilia, 158-159
timing, considerations for, 140
Genomics, 135
Gershoni-Baruch syndrome, 80
Gestational age
CDH diagnosis and, 72
first trimester screening and, 228-229
intracranial hemorrhage and, 16
nuchal translucency and, 196
for nuchal translucency measurement, 190
Gestational diabetes, multiple gestation and, 343
GJB6 gene deletion, 179
Glomerular filtration rate, in multiple gestation, 339
Glucose levels, inborn errors of metabolism and, 166
GnRH antagonists, 357
Goltz syndrome, 79
Gonadotropins, for controlled ovarian hyperstimulation, 356-358
GPC3 haploinsufficiency, CDH and, 78-79
Growth factors, in lung development, 87
Growth failure, in CDH survivors, 130

Harmonic scalpel, for selective termination, 333, 334
hCG. *See* Human chorionic gonadotropin
Health care costs, first trimester screening and, 263
Health care providers, role in newborn screening, 184-185
Hearing loss, congenital
audiological characteristics of, 174
in congenital diaphragmatic hernia survivors, 132
in ECMO-treated infants, 20, 132
ethical issues, 179-180
etiology, diagnosis of, 176-179
genetic causes of, 175-176, 177

Hearing loss, congenital (*Continued*)
genetic counseling for, 179-180
interventions/management of, 179
molecular genetic testing for, 148, 173
nongenetic causes of, 176
prevalence of, 173
risk factors, 173, 174
temporary causes of, 174-175
Heart/lung machine, complications from, 2
Heart transplantation, ECMO as bridge for, 36
HELLP syndrome, 156-157, 309-310
Hematocrit, perfusion, 53-54
Hematologic system
abnormalities, in inborn errors of metabolism, 168
in multiple gestation, 340
Hemisphere specialization, in ECMO-treated infants, 62-63
Hemochromatosis, molecular genetic testing for, 148
Hemodilution, during cardiopulmonary bypass, 53-54
Hemoglobinopathies, 182
Hemostasis, 38
Heparin, prophylactic antenatal for inherited thrombophilia, inherited, 158, 159-160
Heparin induced thrombocytopenia, pregnancy-associated, 160
HFOV (high frequency oscillatory ventilation), 11, 113, 115
HFV (high frequency ventilation), 12-13
HFV (high frequency ventilation), before ECMO cannulation, 12-13
Higher-order multiple gestation
gestational age at delivery and, 306
incidence, 305, 338
management, 306-310
maternal morbidity in, 309
obstetrical complications, 309
outcome, 305-306
parity, gestational age and, 305-306
placentation and, 306
rates, 322
risks of, 307
High frequency oscillatory ventilation (HFOV), 11, 113, 115
High frequency ventilation (HFV), 12-13
High-risk subgroups, 364
Home uterine activity monitoring (HUAM), 308
Hormonal modulation, of lung development, 89-90
HRSA (Health Resources and Services Administration), newborn screening and, 183-184
Human chorionic gonadotropin (hCG), 203. *See also* Quadruple serum screen; Triple screen
beta-subunit, 260, 314-315. *See also* Free βhCG
BUN study, 236-238
detection rate for given false-positive rate, 253-256
discriminatory value *vs.* free βhCG, 371-372
hyperglycosyated, 206-207
intact *vs.* free, 197-198
Humerus length determination, in genetic sonogram, 388-389
Huntington disease, molecular genetic testing for, 148
Hydrops, on CDH ultrasound, 72
Hydrotherapy, 308
Hyperammonemia, 167, 170
Hyperbilirubinemia, neonatal, 167-168, 176
Hypercapnia, 45, 46
Hyperechoic bowel, on genetic sonogram, 389
Hyperhomocysteinemia, 153-154
Hypertensive disorders of pregnancy
cerebral damage from, 46
in multiple gestation, 307, 309-310
multiple gestation and, 343
Hyperventilation, reduction of cerebral blood flow, 46
Hypoglycemia, neonatal, 166
Hypoglycorrhachia, 166
Hypotension, cerebral damage from, 46
Hypothermia, postischemic, 55-56
Hypothyroidism, congenital, 182
Hypoxemic respiratory failure, ECMO for, 118
Hypoxia
brain response to, 45-46
hearing loss associated with, 176
lactate serum levels and, 165-166
prolonged with vessel ligation, 46-47

ICH. *See* Intracranial hemorrhage
ICI (intracervical insemination), 356
Idiopathic persistent pulmonary hypertension of the newborn, 9-10
IEMs. *See* Inborn errors of metabolism
Iliac angle, in Down syndrome, 390
Implantation rate, assisted reproductive technology and, 358-359
Inborn errors of metabolism (IEMs)
acetylcarnitine analysis, 170-171
amino acid analysis, 170
ammonia and, 167
complete blood count, 168
congenital anomalies with, 171
electrolytes/blood gas analysis for, 164-165
fatal, diagnostic work-up for, 171
glucose levels in, 166
ketones in, 166-167
liver status and, 167-168
metabolic testing, specialized, 168, 169
newborn screening, 168
organic acid analysis, 168-170
treatment, 171-172
urinalysis for, 165
urine odors in, 165
Independent sequential screening
in BUN Study, 276
definition of, 253
detection rate for given false-positive rate, 253-256
detection rates, 221
Infectious agents, causing hearing loss, 176
Informed consent
ethics of, 277-278
for fetoscopic endoluminal tracheal occlusion, 96
for invasive testing, 193
Inhaled nitric oxide therapy (iNO)
for congenital diaphragmatic hernia, 113
discontinuation of, 12
dosing, 11
initiation of therapy, 11-12
in non-ECMO center, 12
for PPHN, 11-12
for pulmonary hypertension in CDH, 41, 123-126
use before ECMO cannulation, 12-13
Inherited thrombophilias. *See* Thrombophilias, inherited
Inhibin A. *See also* Quadruple serum screen
detection rate for given false-positive rate, 253-256
integrated screening results and, 220-221
reliability of, 205
in second trimester screening, 204-206
iNO. *See* Inhaled nitric oxide therapy
Integrated screening test, 233-234, 248-251. *See also* Serum integrated screening test
definition of, 226, 247
Down syndrome detection rates for, 220-221
economic analyses, 264-265
efficacy, *vs.* other screening approaches, 227-228
false-positive rates, 229-230, 247
performance, risk cut-off and, 232-233
sequential nondisclosure, 372
vs. combined screening test, 372-373
vs. serum integrated screening test, 251

Interhemispheric fissures, in ECMO-treated infants, 47, 59
International CDH Registry, 112
Intracardiac focus, echogenic, 389
Intracervical insemination (ICI), 356
Intracranial hemorrhage (ICH)
  birth weight and, 16
  as contraindication for ECMO, 17
  from ECMO, 19-20
  ECMO deaths and, 47
  in ECMO-treated premature infants, 59
  exclusion from ECMO and, 42
  gestational age and, 16
  ultrasound imaging of, 59-60
Intraoperative support, ECMO for, 36
Intrauterine fetal demise (IUFD)
  congenital diaphragmatic hernia and, 69
  multiple gestation and, 341-342
  of one fetus in multiple gestation, 283-285
Intrauterine growth restriction (IUGR)
  multiple gestation and, 342-343
  prevention, 343
  risk factors, 342
  thrombophilia and, 154, 155-156, 157
Intrauterine insemination, with controlled ovarian hyperstimulation, 356-357
Invasive prenatal diagnostic testing. *See also* Amniocentesis; Chorionic villus sampling
  access issues, 270
  for advanced maternal age, 364
  current data, 216-217
  historical perspective, 215-216
  in multiple gestation, 316-318
  pregnancy loss and, 215
  second-trimester, 238
  second-trimester, risk cut-off for, 238
  sensitivity/specificity of, 268, 391
  sonographic markers, 192
  SURUSS Trial. *See* SURUSS Trial
  two-stage screening, risk-oriented, 192-193
  types of tests, definition of, 226
In vitro fertilization (IVF), 321, 357
  adverse outcomes, 360
  COH conversion to, 356
  double embryo transfer, 359
  higher order multiple pregnancies and, 355
  risk of multiple pregnancy and, 358
  single embryo transfer, 359-360
  twinning rates, 359
iPPROM, after FETO, 102
IQ
  of ECMO-treated children, 62
  in TTTS survivors, 302
Iron status, in multiple gestation, 351
IUFD. *See* Intrauterine fetal demise
IUGR. *See* Intrauterine growth restriction
IVF. *See* In vitro fertilization

Jugular vein ligation, effects on brain, 46-47

Karyotype analysis
  abnormality, nuchal translucency and, 408-409
  normal, with increased fetal NT and CHD, 193-194
Ketones, inborn errors of metabolism and, 166-167

Lactate serum levels, inborn errors of metabolism and, 165-166
Language deficits, of ECMO-treated infants, 62-63
Laser coagulation, for selective termination, 333, 334
LCOS (low cardiac output syndrome), 35
L/D (liver/diaphragm ratio), 74
Left heart hypoplasia, aortic coarctation or stenosis in, 200-201
Left heart return, 53
Left ventricular hypoplasia, 73, 124
Legislation, on assisted reproductive technology practices, 360
Limb reduction defects, after chorionic villus sampling, 404-405
Liver/diaphragm ratio (L/D), 74
Liver herniation
  in CDH, 71, 72, 74
  FETO selection criteria and, 96, 100, 102
Liver lock, 108
Liver status, inborn errors of metabolism and, 167-168
L-NAME, 48
Low cardiac output syndrome (LCOS), 35
Low molecular weight heparin, prophylactic antenatal for inherited thrombophilia, inherited, 158, 159-160
LOX gene family, CDH and, 83
Lung development
  in CDH, 91
  in congenital diaphragmatic hernia, 95
  genetic factors, 87, 88
  growth factors in, 87
  hormonal modulation of, 89-90
  lung bud formation, 86-87
  onset of, 87
  perfluorocarbon-induced, 113, 115
  phases of, 86
  retinoic acid in, 88
  sonic hedgehog pathway in, 87-88
  surgical modulation of, 90
  vascular abnormalities in CDH, 88-89
Lung disease
  chronic, 16, 20, 130
  reversible, ECMO for, 16
Lung hypoplasia
  CDH development and, 5, 10, 91, 115
  CDH prognosis and, 72, 73-74
Lung-to-head ratio (LHR), in CDH
  assessment procedure, 72-73
  in fetal surgery criteria, 108
  as FETO selection criteria, 96, 99, 100, 102
  neonatal morbidity/mortality and, 95
  prognosis and, 105-106
Lymphatic obstruction sequence, 199-200

Magnesium sulfate, for tocolysis, 309
Magnesium supplementation, 351
Magnetic resonance imaging (MRI)
  CDH evaluation and prognosis, 73-74
  cerebrovascular imaging of ECMO-treated infants, 60
Maple syrup urine disease (MSUD), 165, 167
Marfan syndrome, 78, 79-80
MAS (meconium aspiration syndrome), 9, 119
Maternal age, advanced
  assisted reproductive technology and, 322-323, 358
  chromosomal defect risk and, 191
  combined first-trimester screening and, 236-238
  definition of, in multiple gestation, 313-314, 398
  as Down syndrome screening method, 367
  in first trimester Down syndrome screening, 219
  invasive testing for, 364
  live births and, 350
  obstetric complications and, 244-245
  as screening test, 364
Maternal body mass index, obstetric complications and, 244
Maternal Fetal Medicine Foundation (MFMF), 369, 385
Maternal morbidity, in higher-order multiple gestation, 309
Maternal serum markers, first trimester abnormalities, adverse outcomes and, 411
Mathew-Wood syndrome, 80

Meacham syndrome, 80
Mechanical ventilation
  for congenital diaphragmatic hernia, 114-115
  ECMO for neonatal respiratory failure and, 16
  for PPHN, 10-11
Meconium aspiration syndrome (MAS), 9, 119
Medical education, on newborn screening, 185
Membrane oxygenators, ECMO, 4, 37, 38
Mental retardation, FISH analysis of, 145-146
Metabolic acidosis, inborn errors of metabolism and, 164-165
Metabolic testing, specialized, for inborn errors of metabolism, 168, 169
Metformin, for ovulation induction, 356
MFMF (Maternal Fetal Medicine Foundation), 369, 385
MFPR. *See* Multifetal pregnancy reduction
Microdeletion syndromes, FISH analysis of, 145
Microduplication syndromes, FISH analysis of, 145
Microphthalmia with linear skin defects, 79, 81
Microporous membrane lungs, 4-5
Microseptostomy, for twin-to-twin transfusion syndrome, 300
Mineral supplementation, 351-352
Molecular genetic testing laboratories, 136, 144
Molecular genetic tests, 146-149
  decision-making for, 146
  disorders diagnosed by, 146-148
  evaluation for clinical practice, 138
MoM (Multiples of the median), 191, 197, 274, 275
Monoamniotic twins, 290-292
Monochorionicity, ultrasound determination, 407-408
Monochorionic pregnancies, selective termination
  complications from, 330-331
  cord ligation, 331-333
  cord occlusion methods, 331
  counseling for, 335
  future investigations, 336
  indications for, 331
  maternal anesthesia, 333, 335
  maternal complications, 335
  pregnancy complications, 335
  screening of surviving fetus, 335
  technical considerations, 335-336
  thermocoagulation methods, 333, 334, 335
Morgagni hernia, 69
Mosaicism, confined placental, 403
MRFs (myogenic regulatory factors), 82
MRI. *See* Magnetic resonance imaging
MSUD (maple syrup urine disease), 165, 167
MTHFR C677T gene mutation, 153-154
Multifetal pregnancy reduction (MFPR)
  clinical uses, 323
  demographics, 321-323
  historical aspects, 323
  results, 323-326
  societal issues, 326-328
Multiple gestation
  aneuploidy risk in, 312-314, 397-398
  with anomalous fetus, management of, 400
  artificial reproductive technology and, 396
  chromosomal abnormality risk and, 396
  combined screening, first trimester, 315-316, 399-400
  complications of, 338-345
  defining advanced maternal age in, 398
  definition of advanced maternal age and, 313-314
  determination in first trimester screening, 407-408
  discordant fetal abnormalities, 282-283
  essential fatty acid requirements, 352
  fetal reduction. *See* Multifetal pregnancy reduction
  genetic counseling for, 313
  higher-order. *See* Higher-order multiple gestation
  incidence, 305, 338
Multiple gestation (*Continued*)
  intrauterine demise of one fetus, 283-285
  invasive prenatal diagnostic testing, 316-318
  iron status in, 351
  maternal physiologic adaptations in, 338-340
  neural tube defect screening, 316
  nuchal translucency, first trimester, 315, 399
  nutrition and, 349-353
  perinatal mortality/morbidity, 338, 339
  preterm delivery of one fetus, 287-290
  preterm premature rupture of membrane, 285-287, 289
  prevalence, 312
  quadruple serum screen, 396
  rates, 259, 321, 322
  second trimester screening for aneuploidy, 398-399
  selective termination in, 283
  structural abnormality screening, 316
  vitamin and mineral supplementation, 351-352
Multiples of the median (MoM), 191, 197, 274, 275
Multivitamin supplementation, 351-352
Myogenic regulatory factors (MRFs), 82

Nasal bone analysis
  absence, as Down syndrome marker, 198-199, 370, 390-391
  first trimester evaluation, in FASTER trial, 242-243
National Newborn Screening and Genetics Resource Center (NNS-GRC), 184
ND:YAG laser coagulation, for selective termination, 333, 334
Neonatal respiratory failure, ECMO for, 3
  complications, 19-20
  current status of, 4
  demographic changes in, 20-21
  duration of, 19
  ECMO team for, 17
  historical aspects of, 15
  indications for, 16-17
  outcome, 20, 22
  patient management, 18-19
  procedure, 17-18
  randomized controlled trials for, 15-16
  survival rates, 20, 22
Neural tube defect screening, in multiple gestation, 316
Neurocognitive deficits, in congenital diaphragmatic hernia survivors, 131-132
Neurodevelopmental changes, in twin-to-twin transfusion syndrome, 302-303
Neuropsychological assessment, of ECMO-treated children, 61-62
Newborn screening
  advancing developments in, 185-186
  core panel for, 183, 184
  development of, 182
  ethical considerations, 186-187
  for hearing, 173-174
  for inborn errors of metabolism, 168
  provider's role in, 184-185
  public considerations, 186-187
  public health systems and, 182-184
NICHD Multicenter Down Syndrome Screening Study, FASTER trial and, 240-241
NIH-ECMO trial, 3
NINOS trial, 12, 41
NIPBL gene, 80
Nitric oxide
  idiopathic PPHN and, 9-10
  inhaled. *See* Inhaled nitric oxide
Nitrofen-induced CDH, 81-82
NNS-GRC (National Newborn Screening and Genetics Resource Center), 184
NO-cGMP pathway, in congenital diaphragmatic hernia, 124
NOMO (no-oxygenator membrane oxygenation), for cardiac patients, 29

Nondisclosure sequential screening method, 253-256, 372
Nonsteroidal antiinflammatory drugs, idiopathic PPHN and, 9
Noonan syndrome, 200
Nuchal fold thickness. *See* Nuchal translucency ultrasound
Nuchal translucency ultrasound, 209. *See also* Genetic sonogram
  abnormal measurements, 381-382
  access issues, 269-270
  accurate, criteria for, 378-380
  BUN Study, 236-238, 383-385
  causes of increased thickness, 368
  center-specific medians, 197
  clinical applications, 380
  combined with other screens, 209, 275-276
  congenital heart disease and, 410-411
  cost-benefit analysis, 269
  cystic hygroma determination, 408-409
  definition of, 195, 368, 377
  delta-NT values, 382
  detection rate, 381
  Down syndrome detection rate, 196, 377, 391, 392
  in Down syndrome *vs.* normal fetuses, 195, 211-212
  economic analyses of, 264-265
  enlarged, cardiac anomalies and, 199-201
  FASTER trial quality review method, 385
  with first trimester serum screening, 372
  gestational age cut-offs, 382
  gestational-specific cutoffs, 275
  high, with normal karyotype, 193-194
  importance of quality review, 382
  increased, 408-409
  integrated screening results and, 220-221
  interpretation of, 275
  karyotype abnormalities and, 408-409
  likelihood ratios, 191, 196-197
  and maternal age, 191-192
  with maternal free β-hCG and PAPP-A, 192
  with maternal serum levels, 406
  measurement technique, 190-191
  median MoM values, 231-232
  MFMFNTQR quality review method, 385
  MFMP sonographic criteria, 369
  MoM values, 197, 382
  in multiple gestation, 259-261, 315, 399
  NTQR credentialing, 377-378
  obtaining, success rates for, 229, 368-369
  ongoing quality assurance for, 274-275
  quality assessment, 191
  quality assurance, ongoing, 274-275
  quality review methods, 382-383
  screening performance, 268-269, 369-370
  septated lesions. *See* Cystic hygroma
  sonographer training and, 272-273
  spontaneous abortion and, 219-220
  standardized technique, 190-191, 237, 273-274, 381-382
  thickness variability, Down syndrome risk and, 191, 382
  training, 191, 382-383
  in twin pregnancies, 192
Nutrition, multiple gestation and, 349-353
Nutritional morbidity, in CDH survivors, 130

OAE (otoacoustic emissions screening), 174
Obesity, obstetric complications and, 244
Obstetric complications
  first trimester vaginal bleeding and, 243-244
  in higher-order multiple gestation, 309
  maternal age and, 244-245
  maternal body mass index and, 244
  PAPP-A and, 244, 245
  from selective termination, 335
Oligohydramnios, PPROM in multiple gestation and, 286
Opitz G/BBB syndrome, 79
Organic acid analysis, for inborn errors of metabolism, 168-170, 185-186
Orthopaedic deformities, in congenital diaphragmatic hernia survivors, 132
Otoacoustic emissions screening (OAE), 174
Ototoxic medications, hearing loss associated with, 176, 177
Ovulation induction, 356-360
Oxygenators, ECMO, 4, 37, 38

$PaCO_2$, in CDH survivors *vs.* nonsurvivors, 115
PAGOD syndrome, congenital diaphragmatic hernia and, 79, 80
PAP (pulmonary artery pressure), 8, 125
Papillary muscle, macrocalcifications in, 389
PAPP-A. *See* Pregnancy-associated plasma protein A
Parenchymal lung disease, responsiveness to iNO, 12
Particulate emboli, in ECLS, 52
Pectus deformity, in congenital diaphragmatic hernia survivors, 132
Pediatric respiratory failure patients, survival rates, 28
Perfluorocarbon instillation, for congenital diaphragmatic hernia, 113, 115
Perfusate, for ECMO
  oxygen management, 56
  pH, 54-55
  temperature, 55-56
Perfusion flow rate, inadequate, brain ischemia from, 53
Perlman syndrome, CDH and, 79
Peroxisomal disorders, 171
Persistent pulmonary hypertension of the newborn (PPHN)
  idiopathic or black-lung, 9-10
  meconium aspiration syndrome and, 9
  respiratory failure and, 3
  treatment of, 10-12
PGM (prothrombin gene mutation G2010A), 150, 153, 155, 157
pH, in CDH survivors *vs.* nonsurvivors, 115
Pharmacogenomics, DNA-based genetic testing and, 141
Phosphodiesterase inhibitors, 126
Phospholipase A2, 9
pH stat strategy, 54-55
PKU, newborn screening for, 182
Placental abruption, thrombophilia and, 155-156, 157
Plasminogen activator inhibitor-1 (PAI-1), elevated levels of, 153
Pleuroperitoneal fold (PPF), 90
Pneumothorax, meconium aspiration and, 9
Polycystic ovarian syndrome (PCOS), ovulation induction in, 356
Polyhydramnios, 72, 131
Polymorphisms, in congenital diaphragmatic hernia, 83
Posterior-fossa hemorrhage, in ECMO population, 47
PPF (pleuroperitoneal fold), 90
PPROM. *See* Preterm premature rupture of membrane
Prader-Willi syndrome, testing for, 147
Preeclampsia, thrombophilia and, 154, 155-156
Pregnancy
  antithrombin deficiency in, 152
  hemostatic changes in, 150-151
  physiologic adaptations in multiple gestation, 338-340
  physiological stresses, in higher-order multiple gestation, 307
  protein C deficiency in, 152-153
  protein S deficiency in, 151-152
  protein Z deficiency in, 152
  thrombin activation markers in, 151
Pregnancy-associated plasma protein A (PAPP-A), 276
  BUN study, 236-238
  in combined screening test. *See* Combined screening test
  detection rate, 253-256, 371
  for Down syndrome screening, 272
  with free βhCG, NT and maternal age, 197
  integrated screening results and, 220-221
  in multiple gestation, 259
  with NT measurement, 372
  obstetric complications and, 244, 245

Pregnancy dating, first trimester screening for, 406-407
Pregnancy-induced hypertension, in multiple gestation, 307, 309-310, 343
Pregnancy loss. *See also* Intrauterine fetal demise; Spontaneous abortion
  early, inherited thrombophilias and, 154-158
  inherited thrombophilias and, 154-158
  from invasive prenatal diagnostic tests, 215
  from multifetal pregnancy reduction, 323-326
  multiple gestation and, 341
  in multiple pregnancies, 321
Preimplantation genetic diagnosis (PGD), 359
Prematurity, risks, fetal number and, 321, 322
Preterm delivery, risks of, 305
Preterm labor and birth
  multiple gestation and, 308-309, 344-345
  prevention of, 345
Preterm premature rupture of membrane (PPROM)
  multiple gestation, 285-287, 289, 343-344
  from selective termination, 335
Prevalence, predictive values and, 365-366
Progesterone supplementation, for preterm birth prevention, 345
Prostacyclins, 126
Prostacyclin signaling pathway, 8-10
Protein C deficiency, 152-153
Protein S deficiency, 151-152
Protein Z deficiency, 152
Prothrombin gene mutation G2010A (PGM), 150, 153, 155, 157
Public health systems
  access to Down syndrome screening, 269-270
  Down syndrome patient and provider education, 270-271
  of Down syndrome screening, 267-271
  newborn screening and, 182-184
  of nuchal translucency screening, 268-269
  of second trimester screening, 270
Pulmonary arterial system, development of, 10
Pulmonary artery pressure (PAP), 8, 125
Pulmonary hemorrhage, ECMO for neonatal respiratory failure and, 16-17
Pulmonary hypertension, 119
  in CDH pathophysiology, 40, 115
  ECMO for, 35-36
  late, in CDH, 124-127
Pulmonary hypoplasia, 10, 119-120
Pulmonary morbidity, from congenital diaphragmatic hernia, 129-130
Pulmonary vascular resistance, in CDH neonates, 123, 125
Pulmonary vascular transition, 8-9
Pulmonary vasoconstrictors, 8
Pulmonary vasodilator therapy, for CDH, 123-127
  inhaled nitric oxide. *See* Inhaled nitric oxide therapy
Pyelectasis, 389
Pyruvate serum levels, inborn errors of metabolism and, 165-166

Quadruple serum screen
  definition of, 226
  detection rate, 204-205, 231, 272, 371
  economic analyses, 264-265
  efficacy, vs. other screening approaches, 227-228
  false-positive rates, 229-231, 272, 371
  FASTER trial and, 205-206, 272
  with genetic sonogram, 212-213
  markers for, 276, 367, 371. *See also specific serum markers*
  in multiple gestation, 396
  performance, risk cut-off and, 232-233
Qualitative review, for NT quality assessment, 383
Quality assurance system, for nuchal translucency measurement, 274-275
Quantitative review, for NT quality assessment, 383
Quintero staging system, for twin-to-twin transfusion syndrome, 297

Radiofrequency ablation, for selective termination, 333, 334, 335
RARs (retinoic acid receptors), 88
Renal physiology, in multiple gestation, 339
Respiratory alkalosis, in neonates, 165
Respiratory distress syndrome, ECMO for, 119
Respiratory failure
  in adults, ELSO for, 2-3, 25, 28, 31
  in neonates, ELSO for, 25-27, 31
  in pediatric patients, ELSO for, 25, 27-28, 31
Respiratory system, maternal, in multiple gestation, 339-340
Retinoic acid, in lung development, 88
Retinoic acid receptors (RARs), 88
Retinoic X receptors (RXRs), 88, 89
Right hemisphere vulnerability, of ECMO-treated infants, 62-63
RXRs (retinoic X receptors), 88, 89

Scoliosis, in congenital diaphragmatic hernia survivors, 132
Screening tests. *See also* First trimester screening; Second trimester screening; *specific screening tests*
  alternative strategies. *See* Contingent sequential screening; Sequential screening
  predictive values, prevalence and, 365-366
  results from, 364
  sensitivity/specificity of, 268, 364-365, 366
  statistics and, 366
  vs. diagnostic tests, 364, 365
Second trimester screening. *See also specific analytes*
  analytes, 220, 253
  for aneuploidy risk, 314-315
  contingent on first trimester screening. *See* Contingent sequential screening
  detection rates, 253-256, 267
  DNA microarray technology for, 138
  Down syndrome detection rates, 220, 367
  false-positive rates, 267
  genetic sonogram for. *See* Genetic sonogram
  in higher-order multiple gestation, 306-307
  hyperglycosyated hCG for, 206-207
  inhibin A addition to, 204-206
  intact *vs.* free hCG, 197-198
  integrated with first trimester tests, 220-221
  in multiple gestation, 398-399
  in patients with negative first trimester screens, 237
  public health implications, 270
  quad marker profiles for. *See* Quadruple serum screen
  sequenced with first trimester tests, 221
  triple-marker. *See* Triple screen
Selective termination
  in dichorionic twin gestation, 330
  indications for, 331
  in monochorionic pregnancies, 283, 330-336
Sensitivity, of screening tests, 364-365, 366
Sensorineural hearing loss. *See* Hearing loss, congenital
Sepsis
  ECMO for, 28, 119
  in infants, intracranial hemorrhage and, 59
Sequential screening
  contingent model for. *See* Contingent sequential screening
  Down syndrome detection rates, 221, 272, 374
  economic analyses, 264-265
  false-positive rates, 373-374
  step-wise model. *See* Step-wise sequential screening
Serum integrated screening test
  comprehension/acceptance of, 250-251
  definition of, 226, 248
  efficacy, *vs.* other screening approaches, 227-228
  false-positive rates, 229-230
  overview of study method, 248
  patient satisfaction survey, 248-250
  performance, risk cut-off and, 232-233
  prenatal care professional survey, 249, 250
  sonographer-specific medians and, 232
  vs. full integrated screening, 251

Serum integrated serum screening test, economic analyses, 264-265
Serum Urine and Ultrasound Screening Study. *See* SURUSS Trial
SET (single embryo transfer), 359-360
SGBS (Simpson-Golabi-Behmel syndrome), 78-79
sGC (soluble guanylate cyclase), 8
Sickle cell disease, 147
Silicone rubber membranes, 2
Sim2 gene, 82
Simpson-Golabi-Behmel syndrome (SGBS), 78-79
SIN-1, 48
Single embryo transfer (SET), 359-360
Single-gene disorders, 135-138
Slit genes, in CDH, 82
SMA I, 147
Soluble guanylate cyclase (sGC), 8
Sonic hedgehog pathway, in lung development, 87-88
Sonographer training, for NT ultrasound, 272-273, 382-383
Specificity, of screening tests, 364-365, 366
SPECT (single photon emission computed tomography), 60
Spinal deformities, in congenital diaphragmatic hernia survivors, 132
Spondylcostal dysostosis, 78, 79
Spontaneous abortion
  inherited thrombophilias and, 154-156
  multiple gestation and, 341
  nuchal translucency measurement and, 219-220
Staging systems, for twin-to-twin transfusion syndrome, 297-298
Starling curve, 52
State government, newborn screening and, 184
Statistics, screening tests and, 366
Step-wise sequential screening
  definition of, 253
  detection rates, 221-222, 233-234, 253-256
  false-positive rates, 233-234, 253-256, 374
Stomach, within thorax, in CDH, 71, 72
Structural anomalies
  with congenital diaphragmatic hernia, 69, 70, 77
  first trimester diagnosis of, 408
  prognosis for CDH and, 72
  screening for, in multiple gestation, 316
  in twin pairs, selective termination for, 331
Subtelomeric rearrangements, FISH analysis of, 145-146
Sulfite oxidase deficiency, 170
Superior vena cava cannula, obstruction, 53
Surfactant
  deficiency in CDH, 89
  meconium and, 9
  metabolism in ECMO-treated CDH infants, 89
Surfactant inhibitors, 9
Surfactant therapy
  for CDH, 89
  for congenital diaphragmatic hernia, 41
  for PPHN, 11
  prophylactic, for CDH, 113, 114
  use before ECMO cannulation, 12-13
Surgical correction, of congenital diaphragmatic hernia, timing of, 113, 114
SURUSS trial, 225, 367
  combined first trimester markers, 372
  combined test and, 374
  contingency screening and, 374
  cystic hygroma and, 370
  design, avoidance of bias in, 231
  efficacy and safety of screening tests, 233-234
  FASTER Trial and, 231
  first trimester combined screen *vs.* integrated screening, 372-373
  free βhCG vs second-trimester hCG, 198
  h-hCG, 206-207
  mean of two NT measurements and, 274
  methods, 226-227, 230
  NT median MoM values, 231-232
SURUSS trial, 225, 367 (*Continued*)
  NT screening performance, 195, 268-269
  PAPP-A measurements, 232-233
  results, 227-230
  screening test performances, risk cut-off and, 232-233
  success rates for NT measurements, 368
  triple *vs.* quad markers, 204-205

TAFI (thrombin activatable fibrinolysis inhibitor), 150, 151
Tandem mass spectrometry (MS/MS), for newborn screening, 184, 185-186
TAPVC (total anomalous pulmonary venous connection), 34-35
Teratogens, congenital diaphragmatic hernia and, 81
Thermocoagulation methods, for selective termination, 333, 334, 335
Three-dimensional ultrasound, prenatal evaluation of CDH, 73
Thrombin activation markers, in pregnancy, 151
Thrombophilias, inherited
  antenatal prophylactic heparin for, 158-160
  Factor V Leiden. *See* Factor V Leiden
  MTHFR C677T gene mutation, 153-154
  PAI-1 activity elevations, 153
  in patients with adverse pregnancy outcomes, 154-157
  prevention of adverse pregnancy outcomes in, 159-160
  prothrombin gene mutation, 150, 153
  screening for, 158-159
Thyroid hormones, lung development and, 89-90
Tocolytic drugs, 309, 345
Total anomalous pulmonary venous connection (TAPVC), 34-35
Tracheal occlusion removal, to reduce CDH severity, 90
Transforming growth factor β, in lung development, 87
TRAP sequence, 330, 336
Tricuspid regurgitation, first trimester screening, 371
Triple screen
  clinical use of, 203-204
  definition of, 226
  detection rates, 371
  efficacy, *vs.* other screening approaches, 227-228
  false-positive rates, 229-230
  with inhibin-A. *See* Quadruple serum screen
  serum markers, 371
  vs. first trimester NT ultrasound for twins, 315
Triplet pregnancy
  maternal weight gain in, 353
  reduction to twin pregnancy, 323-326
Trisomies
  21, CDH and, 81, 82. *See also* Down syndrome screening
  combined screening method for, 237
  ECMO and, 17
  fetal death and, 191
  nasal bone absence and, 199
  sonographic markers, 192
TTTS. *See* Twin-twin transfusion syndrome
Turner syndrome
  cystic hygroma and, 370
  in monozygotic twin, 313
  nasal bone absence, 199
  sonographic markers, 192
  webbed neck, coarctation of aorta and, 200
Twin peak sign, 306
Twins
  acardiac, 330. *See also* Twin-twin transfusion syndrome
  aneuploidy risk and, 397-398
  chorionicity determination, 258-259
  chorionic villus sampling in, 317-318
  conjoined, 260-262, 292-293
  dietary recommendations for, 350
  dizygotic, 258, 313
  first-trimester risk assessment, 192, 258-262
  iron status in, 351
  monoamniotic, 290-292

Twins (*Continued*)
monozygotic, 258, 312-313, 330
monozygotic monochorionic, risks for, 330
rates, 259, 321, 359
risk to surviving fetus following demise of one fetus, 283-284
single fetal demise, management of, 284-285
triple screen *vs.* first trimester NT ultrasound, 315
Twin-twin transfusion syndrome (TTTS), 330, 407
amnioreduction for, 299-300, 302
diagnosis, 296-297
echocardiographic changes in, 299
fetoscopic cord coagulation for, 301
fetoscopic laser photocoagulation for, 300-301, 302-303
increased nuchal translucency and, 399
microseptostomy for, 300
neurodevelopmental changes in, 302-303
pathophysiology, 298-299
risk in higher-order multiples, 306
selective termination for, 331
sequential therapy for, 301-302
staging systems for, 297-298

Ultrasound. *See also* Genetic sonogram
assessment of CDH prognosis, 72
cerebrovascular imaging of ECMO-treated infants, 59-60, 61
congenital diaphragmatic hernia diagnosis, 70-71
cranial, for preterm infants, 61
ductus venosus assessment, 370-371
first-trimester markers of chromosomal defects, 192
of higher-order multiple gestation, 307-308
mid-trimester, for Down syndrome screening. *See* Genetic sonogram
monoamniotic twin diagnosis, 290
monochorionicity determination, 407-408
nasal bone analysis. *See* Nasal bone analysis
nuchal translucency measurement. *See* Nuchal translucency ultrasound
prior to FETO procedure, 97
structural anomaly determination in first trimester, 408
twin peak sign, 306
Unconjugated estriol. *See* Estriol, unconjugated
Urine
ketones, inborn errors of metabolism and, 166-167
maternal makers with genetic sonogram, 213
odor, inborn errors of metabolism and, 165
organic acid analysis, for inborn errors of metabolism, 168-170
Urogenital defects, with congenital diaphragmatic hernia, 69, 70

VA ECMO. *See* Venoarterial ECMO
Vaginal bleeding, first trimester, 243-244
Vascular endothelial growth factor (VEGF), 88-89
Vasculature, in congenital diaphragmatic hernia, 88-89
Vasoactive mediator hypothesis, of twin-to-twin transfusion syndrome, 298-299
VA-V support, 36
VEGF (vascular endothelial growth factor), 88-89
Venoarterial ECMO (VA ECMO)
access for, 36
adequacy, monitoring of, 37
annual usage, 26
carotid artery blood flow and, 46-47
for CDH, 120
cerebral autoregulation and, 48
for failure to wean from CPB, 35
intracranial hemorrhage risk and, 19-20
nonpulsatile flow from ECMO pump, 47
for pediatric patients, 27
procedure for, 17-18, 42
"rest" ventilatory settings, 18, 19
transthoracic cannulation for, 38
vessel reactivity to acetylcholine, 48
vs. venovenous ECMO, 27
Venous drainage, during ECLS, 53
Venovenous ECMO (VV ECMO)
access for, 120
for cardiac compromise, 26-27
for CDH, 120
with double lumen catheter, use of, 26
procedure for, 17-18, 42
"rest" ventilatory settings, 18, 19
risk factors, 47
venous drainage decrease and, 59
vessel reactivity to acetylcholine, 48
vs. venoarterial ECMO, 27
weaning off, 19
Ventriculoseptal defect (VSD), 390
Vessel ligation, effect on brain, 46-47
Vitamins, prenatal, 307
VQ mismatch, in CDH survivors, 130
VSD (ventriculoseptal defect), 390
VV ECMO. *See* Venovenous ECMO

Webbed neck, coarctation of aorta and, 200
Weight gain, maternal, 352-353
World Health Organization (WHO), newborn screening and, 184
WT1 mutations, CDH and, 79

"Yom Kippur effect," 350

Zinc supplementation, 351
Zygosity, aneuploidy risk and, 312-313, 397-398